{"ticker": {"uuid": "9fe6f492-28da-4185-9841-d4f3b88a2f16", "symbol": "PCVX", "name": "Vaxcyte\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant", "summary": "Vaxcyte, Inc. announced the retirement of director Heath Lukatch and the appointment of John Markels as a new independent Class II director, effective July 16, 2026. Markels will join the Audit and Compensation Committees and receive compensation, including an annual equity grant", "url": "https://www.stocktitan.net/sec-filings/PCVX/8-k-vaxcyte-inc-reports-material-event-ac96605cc97f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:13:08", "published_display": "15 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 87% Upside Potential in the Biotech Sector", "summary": "Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company with a strong vaccine pipeline, including VAX-24, and an impressive market capitalization of $8.41 billion. Despite being in a pre-revenue stage with a net loss, analysts see significant potential, with an average tar", "url": "https://www.directorstalkinterviews.com/vaxcyte-inc-pcvx-stock-analysis-exploring-an-87-upside-potential-in-the-biotech-sector/4121256201", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:41:47", "published_display": "13 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte to Participate in Upcoming Investor Conferences", "summary": "Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in two upcoming investor conferences in July 2026: the Leerink Partners Therapeutics Forum and the BTIG Virtual Biotechnology Conference. Company management will host one-on-one meetings at both events. Vaxcyte is a clinica", "url": "https://investingnews.com/vaxcyte-to-participate-in-upcoming-investor-conferences/", "source_name": "Investing News Network", "published_at": "2026-07-09T20:09:44", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (PCVX) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) price action, indicating strong sentiment across all horizons and presenting three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It highlights a significant risk-reward short setu", "url": "https://news.stocktradersdaily.com/news_release/21/Why_PCVX_Price_Action_Is_Critical_for_Tactical_Trading_070926074401_1783597441.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T07:44:00", "published_display": "09 Jul 2026 07:44", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte books July investor meetings at two biotech conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNNE1PZ1hsNFo5VWVoR3VVSGY1YVdxektmTU9CVFQ3ME5ycHM1cTREYlpTLVcxeFlDajdDWGpHck1WalIxVFFIYW9zN3BpNWwtc0tZTjBNY2FUTXUtbzkwVENQQjlFN244THJpOFpiMk41ZlFNemtaQjd1MFM2VFJ1MXIxNk9TQ2djeUFHYlB2VFZMdC0xU2pqVmdmbkgzVnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T20:05:00+00:00", "published_display": "08 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?", "summary": "Vaxcyte recently announced progress in its early-stage clinical trial for VAX-A1, a Group A streptococcus vaccine candidate. While this introduces a new potential market, the primary focus for investors remains the VAX-31 pneumococcal vaccine pipeline and managing cash burn. The ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/should-early-vax-a1-trial-progress-require-action-from-vaxcy", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:11:36", "published_display": "07 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte president and CFO sells $572k in company stock", "summary": "Andrew Guggenhime, President and CFO of Vaxcyte, Inc. (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred after Guggenhime exercised stock options for the same number of sh", "url": "https://www.investing.com/news/insider-trading-news/vaxcyte-president-and-cfo-sells-572k-in-company-stock-93CH-4778028", "source_name": "Investing.com", "published_at": "2026-07-07T07:39:19", "published_display": "07 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte president and CFO sells $572k in company stock By Investing.com", "summary": "Andrew Guggenhime, President and CFO of Vaxcyte (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales were part of a Rule 10b5-1 plan, following his exercise of stock options. Vaxcyte stock has seen a 71% return over the past y", "url": "https://m.za.investing.com/news/stock-market-news/vaxcyte-president-and-cfo-sells-572k-in-company-stock-93CH-4357434?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T00:09:36", "published_display": "07 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vaxcyte Inc For: 6 July By Investing.com", "summary": "This article reports a Form 4 filing for Vaxcyte Inc, dated July 6th. The content is brief, primarily serving as an announcement of the filing by Investing.com. It mentions the stock symbol PCVX with a reported -2.45% change.", "url": "https://ca.investing.com/news/stock-market-news/form-4-vaxcyteinc-for-6-july-93CH-4721926", "source_name": "Investing.com Canada", "published_at": "2026-07-06T23:09:36", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vaxcyte, Inc. Insider Trading Activity", "summary": "Vaxcyte, Inc.'s President and CFO, Andrew Guggenhime, reported an insider trading activity where he exercised stock options to acquire 10,000 shares at $5.35 per share, and subsequently sold all 10,000 shares in two open-market transactions. These sales, executed under a Rule 10b", "url": "https://www.stocktitan.net/sec-filings/PCVX/form-4-vaxcyte-inc-insider-trading-activity-a884eaff4a30.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:09:36", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) COO logs 2,250-share sale and option exercise in Form 4", "summary": "Vaxcyte's Chief Operating Officer, Jim Wassil, reported selling 2,250 shares of common stock and exercising an option for 516 shares on July 1, 2", "url": "https://www.stocktitan.net/sec-filings/PCVX/form-4-vaxcyte-inc-insider-trading-activity-5ea714251dda.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:09:36", "published_display": "06 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate plans 10,000-share sale by option exercise \u2014 PCVX", "summary": "An affiliate of Vaxcyte, Inc. (PCVX) has filed a Form 144 to report a proposed sale of 10,000 common shares through the exercise of stock options on July 6, 2026. The filing also indicates a prior sale of 10,000 common shares for $530,000 on June 18, 2026. The proposed sale is va", "url": "https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-50eedc8a254f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:51", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Biotechnology Innovator with an 86.68% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcWZfeXRrN19JMlZIaGFxMGdKdFdWWW9nTWJwVmNPY3k3RDUzZi1hZXVrd1V1V3hJMGZkQ0UyQmZ4VExfaHlNZVktMVF4OFJ3Q1hxd3FYdUlITk43VXF6a19LcGNUbk1KWkFUa0FiMHVBTzdsUzdTUEdRTWktZjVRNHB0aXRUckV5WTNCdjU4eFl6TkROSmFsYjZzQnh4bUxMa0xad0tRVk13T2xiT3VKRVJqMVVxSWFOZWgzRk9UUl9BaWpxcGdZTEF1YXpGbTJHRjhr?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:21:00+00:00", "published_display": "06 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity", "summary": "Vaxcyte (PCVX) is positioned for long-term growth due to its late-stage vaccine programs, particularly VAX-31 and VAX-A1, and expanded manufacturing capabilities. Analysts project significant revenue growth by 2029, with a consensus price target of $109, implying the stock is cur", "url": "https://simplywall.st/narratives/fy908a8s-future-late-stage-vaccine-programs-and-manufacturing-capacity-will-drive-long-term-opportunity?bpId=4648644&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-07-05T06:39:52", "published_display": "05 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownersh", "url": "https://finviz.com/stock?t=PCVX&ty=ocv&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-04T19:10:41", "published_display": "04 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Updates VAX A1 Trial, Is It Still A Bargain?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Options", "summary": "The article provides comprehensive financial data and trading information for Vaxcyte Inc (PCVX), including its last close price, market capitalization, earnings per share, sales figures, and various performance metrics. It also details insider and institutional ownership, short ", "url": "https://finviz.com/stock?t=PCVX&ta=1&p=m&ty=oc&b=1&r=y5&ov=list_strike&s=25", "source_name": "Finviz", "published_at": "2026-07-04T06:09:46", "published_display": "04 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup.", "summary": "Vaxcyte's stock performance is primarily driven by its pneumococcal vaccine pipeline, clinical milestones, and company disclosures. The company, a US-listed vaccine developer on Nasdaq, has its investor relations information as the main public reference point. Its market valuatio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vaxcyte-stock-stays-tied-to-pipeline-progress-nasdaq-listing-and-sec/69681398", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:09", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNcGpCYmQwT3NhTUdVRnFMd0hKQkNBa3Y2UEVzYWtWRkNyOTYwaWxfbmlHQ1VMaGJnd2xzUWcwNUJCSHM1ZDdjdmczY2I2NVNpWVRRVnB4YWRKWUdkeThCX0FlTGJCajlBeU1KdUtWMzVpbHBiZkFZbWMxQWVGcTh2N1BmRjdrMmh6WjgtR255cjdEZmY0SzFaU0JDSFE?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Vaxcyte Inc (PCVX). It details various financial metrics, including market capitalization, income, sales, EPS, P/E ratios, and stock performance, alongside insider and institutional ownership statis", "url": "https://finviz.com/stock?t=PCVX&ta=1&p=d&ty=lf&b=1&r=y1&page=20", "source_name": "Finviz", "published_at": "2026-07-03T05:40:09", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Vaxcyte Shares Recently?", "summary": "A recent insider transaction at Vaxcyte (NASDAQ:PCVX) involved Co-Founder Grant Pickering selling US$1.3m worth of shares at an average price of US$55.22, reducing his holding by 5.4%. This was the largest insider sale in the last year, occurring near the current share price of U", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/have-insiders-sold-vaxcyte-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-02T15:40:45", "published_display": "02 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Vaxcyte For: 1 July By Investing.com", "summary": "The article announces the filing of Form 144 for Vaxcyte on July 1st. It also features current market data for indices, commodities, bonds, and shares, along with trending news and top stock movers, including Vaxcyte's stock performance.", "url": "https://uk.investing.com/news/stock-market-news/form-144-vaxcyte-for-1-july-93CH-4754025", "source_name": "Investing.com UK", "published_at": "2026-07-01T23:56:00", "published_display": "01 Jul 2026 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items", "summary": "A recently filed Form 144 from Vaxcyte, Inc. (PCVX) indicates that director James Wassil completed three sales of 2,250 shares each on April 1, May 1, and June 1, 2026, generating gross proceeds of $131,475.60, $127,870.65, and $111,416.62 respectively. The filing also details up", "url": "https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-42d34689152f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:59", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell Small Cap Comp Growth Benchmark", "summary": "Vaxcyte, Inc. (NasdaqGS: PCVX) has been added to the Russell Small Cap Comp Growth Benchmark. This news follows a series of recent developments for the company, including board changes, insider stock sales, and progress in its vaccine trials for various bacterial diseases. The co", "url": "https://www.marketscreener.com/news/vaxcyte-inc-nasdaqgs-pcvx-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:10:55", "published_display": "29 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vaxcyte, Inc. \u2013 NASDAQ:PCVX", "summary": "This page from TradingView provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX), specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data and trading platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-PCVX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T18:42:56", "published_display": "29 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Health Care Stocks With Whale Alerts In Today\u2019s Session", "summary": "This article highlights unusual options activity, known as \"whale alerts,\" for ten health care stocks. It details bullish, bearish, and neutral sentiment trades on specific call and put contracts for companies like Vaxcyte, SELLAS Life Sciences, Hims & Hers Health, and others. Th", "url": "https://www.benzinga.com/markets/options/26/06/60167720/10-health-care-stocks-whale-alerts-today-s-session", "source_name": "Benzinga", "published_at": "2026-06-29T17:40:55", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2000 Growth Benchmark", "summary": "Vaxcyte, Inc. (NasdaqGS: PCVX), a clinical-stage vaccine company, has been added to the Russell 2000 Growth Benchmark. The company is focused on engineering high-fidelity vaccines to combat bacterial diseases, with a pipeline that includes candidates for pneumonia and Group A Str", "url": "https://www.marketscreener.com/news/vaxcyte-inc-nasdaqgs-pcvx-added-to-russell-2000-growth-benchmark-ce7f5fdede80f027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:28", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing", "summary": "An insider at Vaxcyte, Inc. recently sold shares totaling $1,338,270, as reported in a new SEC filing. This transaction occurred on June 29, 2026, and follows a previous insider share sale on June 22, 2026. Vaxcyte is a clinical-stage vaccine company developing high-fidelity vacc", "url": "https://www.marketscreener.com/news/vaxcyte-insider-sold-shares-worth-1-338-270-according-to-a-recent-sec-filing-ce7f5fdedc8dfe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:40:55", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vaxcyte\u2019s (PCVX) Russell Index Debut Quietly Reframing Its Long\u2011Term Governance And Growth Story?", "summary": "Vaxcyte (PCVX) was recently added to several Russell growth indices and refreshed its board, with Moncef Slaoui joining as an independent director and Jacks Lee transitioning to a manufacturing consultant role. While these moves are positive for profile and governance, the primar", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/is-vaxcytes-pcvx-russell-index-debut-quietly-reframing-its-l", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:11:00", "published_display": "29 Jun 2026 01:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) CEO and family trusts sell 24,237 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSUd4S2dEVjVGdVBRQUg2M0VseElwbFh0X19ZdkFray1hamxqVUZZalRtQ0RpQkJSMWVJMllGRTduaGlmLXNzR0hUZktfTFNvbk5SSlRLd3Q1V0lXanNHVWswbUx6NW1FcVVtRkYxNmpsTktNWE5qR00zOWVtMmJMMksxNzMzbzg0cFBpeHpXbkxpVXRYT0pWY3dBbmppRnhZZnlVNGNxa0c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moncef Slaoui gets 26,061 Vaxcyte (PCVX) options at $52.11 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRGpJUGRRSFUxZ2tNTmVqTHJuYmpXU3FiMm9GWDdXSVFyYThSVXZDM1g4aWJfcFpZeFp2RFRscDZEN1c0SHU0UlJwc1ktTGxIMWNnMC16M0RJcUNxYzBoY0ZfMERRRkRYMmxFZS1CQnZvM1hzVXEtR3ljS3BWZ0o0S09DUW12RG0zbVducGxsT0kzcUNiY3pYZUUwWFBWZkFFSDhJNmNNaHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moncef Slaoui joins Vaxcyte (NASDAQ: PCVX) board as director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQRFN5UTN5QkhSNjlnR3U2N0FUcEFReVhqRzhZN1BSbmtEZ3JQZ2VLQ0tfSko5VlBxRElxSUFtaGF1SXBqYktvWkZDRnp4Y1UyMkdFMzhxT3FjWldSdUNrRmhTVktWRVdZR0xueUJrRW50cTRoTzBHWnQ4UVQwSjZKb0ozRGQxN3V0aEQ1WnVFbmhRNEotRDA4TTE1Q2lBaDdULWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNUGNxWWpxM3dVYmdXVGRpMF8zNnN5THBLdnJHY1VyLTNwSkFxZVFrekNhS2RCd0lLYzhoVUlJbE93NVhKRFhWaGIzVGcwaHpMdHBRTmNfQVhQNXVwbjZIZE1ub3M3bV91QXU3X0gteVp0N2VRUmVzblNnMVJMVjlyQzQ0MjJxRmZCcWJkN2lucE9iNllRNjFHT0FhS3JWOVJ2RWcyV1BfVzFsZW9zd1NkS1pxRHZvRUE5X1lkT2tBSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vaxcyte-pcvx-doses-first-patient-141404145.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:14:04+00:00", "published_display": "22 Jun 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vaxcyte-insider-sold-shares-worth-080640766.html", "source_name": "MT Newswires", "published_at": "2026-06-22T08:06:40+00:00", "published_display": "22 Jun 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (NASDAQ: PCVX) CEO sells 24,461 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTFB6Nk9tWmVFUl9uMG5zYWJSTExrQ0p0ZWd2dEluRUVVWk80V2pPdUdRVFpTYUNVNkRJVnlfQ3ZjdVd2Ni1ocHZLN2pLbFRMbTVscENkMHhSMzczblZhcjhtalBWZWRuV2VPQzd6bjRsX1FITl9xLV9CY0s3UThiMzVOSVRhZ0VNbWhDT2pHQk1Kb2drT0F1ckJaallza2xoV2ZXYkFVb2Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) CFO sells 10K shares under 10b5-1 plan, holds 166K+", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWWJyT3o1bnhLaDd1NVBFZTVRM3F6YW5oemFsWGNYSU81S3p4S0pSMEVaUkhjQVRNRURFQmJ1VlJtSGdkTk9ubm1jbFZaQUlCV1pjQlV2bjV0QXU2a1haa1lfR2ZxU3RBSUx4dnNvR3hYZUt1My1aeHM1aEhLYXI3TjJKcW5kdzJSai10a0E1SEk1anFWSWdOVU1Rc25ZR3Q1UHhTYl9CRXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vaxcyte-pcvx-conducts-initial-dosage-155536532.html", "source_name": "Insider Monkey", "published_at": "2026-06-17T15:55:36+00:00", "published_display": "17 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vaxcyte-doses-first-participant-phase-200500210.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:05:00+00:00", "published_display": "02 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Promising 112% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcGVSVUJod2xKcHZKMGpITUNoVGpXTlVPS3oxdmxlb2lIOTI2STRQdlpiN0xjdDFOV0pYbVN4VlRZcTR4UklDTXY3ZVI0WVRSdlRDTExCaXM2cThJYUZfRVlvOXRQeFVWaFgtV3pTVUVJWUVUVHZoTVpsamZxM1NlOEJmV1NTMmZxVTJwWDgyRFJYem02NTF2LTlGVXV2Rkowajh0cWJoQ1hUc29MV2tCN1YzSENNLWZLN0o5VlV6VDJULXptZTkzXzVEMlVkNnhhQ3JJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/why-vaxcyte-pcvx-8-7-061211721.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T06:12:11+00:00", "published_display": "01 Jun 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOSm13WXoxbHJDVm0wUUJLSHBpZGJWVjJMbVZLMmo0MUtyXy13VUE4M3lfRXBIZzc1dDJKX0ZqU3I4RlVkc3lJYlhpbTYzc1JzVHlwZ2J0VUhnQUZ2aWVvSHhMX3IxNER3elpYT1dVN1BUZndrUTh0LVA5YXBWbzh3X3kyS1lDc1VDQjZIcmFyRzFPVXR2TC1WamExOGx1aHRNajZPSUh6LXVHU0ZIVkctLVBvdE1ZajdicmtweGxNaDdKMVNTMnBCbDZocw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vaxcyte completes three Phase 3 vaccine enrollments; Q4 data next", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRW9QTXpna0pDUVBaTmdpM2FpUmJvOFF6M203bXBmaXJSS1c5TWxFM2dJYnBrQmdfaTZuU2VGQmFRd05SUXl1aUx5NDN4RjRtZVl0ajBpeUFfaGtVd2tpU21NTmJleXNSMHR0WHhNdERwZFZadXB1Ym9pYzFnTFZyZnlTb1o3VU9nR1lsRmxVS21KUGNRVkE2YlhGVzkyTkNDenducTlSX1VwYzNkN0hQTjdrN3FpM1JCV21iSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPUE1WaWpJU2xwOGJqZlJOamZxM3hoam0yOEljUkwwUk9pYU93UENKT2NmN1F0Sl9vQ0ktVUZlUG51NEhsVFRicjExVks1SVlMUkpkS2o0V29RTGdpUzdSX3FweG9Cb2NRczh4dVJ5Y1BMM0hVSjF3SzJyeEJYVTFKTmliazJuRTlSQzI5NWlGUlFXMkhpYmtNWlVrbDgxQ1ByR2ExMS1MM3QwU0FxUi1IR0x4X085RUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQ3J0RE1aM1RzZWRpRXAxTXRuM1hiQW1Mb3NmVmZXQVBnaHBJandxQ0NRczNMODhsd01BamdFclNxTG83MWpPckdwa09ZNGpxTjU2Z1RkNW00ZlVUNXgyYTJOLXFFYVBla3VPMUdVV0RtQkRhazhuZkJENTh1cUtRQjJKUTRFa3FFMDQ2VWF6UWJ3RVpGSm4tc1Q5bnVlX0pGZ3l3c2NZTVdvZVFzS3pmNmlqZGg0WF9rS0tr?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5oekZPd0huTk9IVzM2Q3hqa0tRMTA1cWRudzBQbFF5TXgyR3J2bTQ3SnFiVEtMSDkwWnNzTWoxTEZ6eGFhVm5rMDB4TzdmME1uVFVYc1pIMFp0d0s3Ym1BQmpnOGxiR2dkQ2dzeHo5T0ZnRmZvVXpCUHc5Q3Fndm8?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Vaxcyte (PCVX) So Attractive", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOaVNCSFdRRm5Ta0M4MEhnREJrYVZGWVpsTVNxQzB5b1pab3JfU256VEQzOFBBVHZqYXZMUTlTbE9Sb3g4MWgtc1o0aU9Wa0lRX045OTdUYW5iemFCcUNkb2JLdmxvMVdIZV83NGgxUDFheVhVbmlKS3cxY3NKQWkxTg?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-07T07:00:00+00:00", "published_display": "07 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9YT3FId1YyNm01M2psSkJ6eFFiblZMb0R6V2lpY091YUxKZ2x0QjZUekVBdzlHcWN5c3FheWJsWmhWLUZtWVg0dXRLMHN0Y3RpMEpB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:41:03+00:00", "published_display": "24 Apr 2025 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeTRWRlhWcmctdVc1bVBxWUpVZTlOaDZZbERfUVhyYTFMelpxeDlfTjVzYlliWnIyU0FyVXBIaHFaWEFuTW9NVFlyMUxyWVk1dFd6cTQtTWpSR3NmZ3JrLTlqWFFQY29rS1RIODkyaDVDRjhPU3JfV0FNdFJROGwtY2czWjd4cGk5ZDZVTXV6eVhwaVNOSzdwanNtdHNsNWdYNXk3LTJNRVRlM3FKWk1Kd2o3emM?oc=5", "source_name": "BioProcess International", "published_at": "2025-02-27T08:00:00+00:00", "published_display": "27 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant", "summary": "Vaxcyte, Inc. announced the retirement of director Heath Lukatch and the appointment of John Markels as a new independent Class II director, effective July 16, 2026. Markels will join the Audit and Compensation Committees and receive compensation, including an annual equity grant", "url": "https://www.stocktitan.net/sec-filings/PCVX/8-k-vaxcyte-inc-reports-material-event-ac96605cc97f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:13:08", "published_display": "15 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring an 87% Upside Potential in the Biotech Sector", "summary": "Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company with a strong vaccine pipeline, including VAX-24, and an impressive market capitalization of $8.41 billion. Despite being in a pre-revenue stage with a net loss, analysts see significant potential, with an average tar", "url": "https://www.directorstalkinterviews.com/vaxcyte-inc-pcvx-stock-analysis-exploring-an-87-upside-potential-in-the-biotech-sector/4121256201", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:41:47", "published_display": "13 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte to Participate in Upcoming Investor Conferences", "summary": "Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in two upcoming investor conferences in July 2026: the Leerink Partners Therapeutics Forum and the BTIG Virtual Biotechnology Conference. Company management will host one-on-one meetings at both events. Vaxcyte is a clinica", "url": "https://investingnews.com/vaxcyte-to-participate-in-upcoming-investor-conferences/", "source_name": "Investing News Network", "published_at": "2026-07-09T20:09:44", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (PCVX) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) price action, indicating strong sentiment across all horizons and presenting three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It highlights a significant risk-reward short setu", "url": "https://news.stocktradersdaily.com/news_release/21/Why_PCVX_Price_Action_Is_Critical_for_Tactical_Trading_070926074401_1783597441.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-09T07:44:00", "published_display": "09 Jul 2026 07:44", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte books July investor meetings at two biotech conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNNE1PZ1hsNFo5VWVoR3VVSGY1YVdxektmTU9CVFQ3ME5ycHM1cTREYlpTLVcxeFlDajdDWGpHck1WalIxVFFIYW9zN3BpNWwtc0tZTjBNY2FUTXUtbzkwVENQQjlFN244THJpOFpiMk41ZlFNemtaQjd1MFM2VFJ1MXIxNk9TQ2djeUFHYlB2VFZMdC0xU2pqVmdmbkgzVnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T20:05:00+00:00", "published_display": "08 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Early VAX-A1 Trial Progress Require Action From Vaxcyte (PCVX) Investors?", "summary": "Vaxcyte recently announced progress in its early-stage clinical trial for VAX-A1, a Group A streptococcus vaccine candidate. While this introduces a new potential market, the primary focus for investors remains the VAX-31 pneumococcal vaccine pipeline and managing cash burn. The ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/should-early-vax-a1-trial-progress-require-action-from-vaxcy", "source_name": "Simply Wall Street", "published_at": "2026-07-07T09:11:36", "published_display": "07 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte president and CFO sells $572k in company stock", "summary": "Andrew Guggenhime, President and CFO of Vaxcyte, Inc. (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred after Guggenhime exercised stock options for the same number of sh", "url": "https://www.investing.com/news/insider-trading-news/vaxcyte-president-and-cfo-sells-572k-in-company-stock-93CH-4778028", "source_name": "Investing.com", "published_at": "2026-07-07T07:39:19", "published_display": "07 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte president and CFO sells $572k in company stock By Investing.com", "summary": "Andrew Guggenhime, President and CFO of Vaxcyte (NASDAQ:PCVX), sold 10,000 shares of company stock for approximately $572,836 on July 6, 2026. These sales were part of a Rule 10b5-1 plan, following his exercise of stock options. Vaxcyte stock has seen a 71% return over the past y", "url": "https://m.za.investing.com/news/stock-market-news/vaxcyte-president-and-cfo-sells-572k-in-company-stock-93CH-4357434?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T00:09:36", "published_display": "07 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Vaxcyte Inc For: 6 July By Investing.com", "summary": "This article reports a Form 4 filing for Vaxcyte Inc, dated July 6th. The content is brief, primarily serving as an announcement of the filing by Investing.com. It mentions the stock symbol PCVX with a reported -2.45% change.", "url": "https://ca.investing.com/news/stock-market-news/form-4-vaxcyteinc-for-6-july-93CH-4721926", "source_name": "Investing.com Canada", "published_at": "2026-07-06T23:09:36", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Vaxcyte, Inc. Insider Trading Activity", "summary": "Vaxcyte, Inc.'s President and CFO, Andrew Guggenhime, reported an insider trading activity where he exercised stock options to acquire 10,000 shares at $5.35 per share, and subsequently sold all 10,000 shares in two open-market transactions. These sales, executed under a Rule 10b", "url": "https://www.stocktitan.net/sec-filings/PCVX/form-4-vaxcyte-inc-insider-trading-activity-a884eaff4a30.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:09:36", "published_display": "06 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) COO logs 2,250-share sale and option exercise in Form 4", "summary": "Vaxcyte's Chief Operating Officer, Jim Wassil, reported selling 2,250 shares of common stock and exercising an option for 516 shares on July 1, 2", "url": "https://www.stocktitan.net/sec-filings/PCVX/form-4-vaxcyte-inc-insider-trading-activity-5ea714251dda.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:09:36", "published_display": "06 Jul 2026 22:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Affiliate plans 10,000-share sale by option exercise \u2014 PCVX", "summary": "An affiliate of Vaxcyte, Inc. (PCVX) has filed a Form 144 to report a proposed sale of 10,000 common shares through the exercise of stock options on July 6, 2026. The filing also indicates a prior sale of 10,000 common shares for $530,000 on June 18, 2026. The proposed sale is va", "url": "https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-50eedc8a254f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:10:51", "published_display": "06 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Biotechnology Innovator with an 86.68% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcWZfeXRrN19JMlZIaGFxMGdKdFdWWW9nTWJwVmNPY3k3RDUzZi1hZXVrd1V1V3hJMGZkQ0UyQmZ4VExfaHlNZVktMVF4OFJ3Q1hxd3FYdUlITk43VXF6a19LcGNUbk1KWkFUa0FiMHVBTzdsUzdTUEdRTWktZjVRNHB0aXRUckV5WTNCdjU4eFl6TkROSmFsYjZzQnh4bUxMa0xad0tRVk13T2xiT3VKRVJqMVVxSWFOZWgzRk9UUl9BaWpxcGdZTEF1YXpGbTJHRjhr?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:21:00+00:00", "published_display": "06 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity", "summary": "Vaxcyte (PCVX) is positioned for long-term growth due to its late-stage vaccine programs, particularly VAX-31 and VAX-A1, and expanded manufacturing capabilities. Analysts project significant revenue growth by 2029, with a consensus price target of $109, implying the stock is cur", "url": "https://simplywall.st/narratives/fy908a8s-future-late-stage-vaccine-programs-and-manufacturing-capacity-will-drive-long-term-opportunity?bpId=4648644&link_type=cta_ai_narrative", "source_name": "Simply Wall Street", "published_at": "2026-07-05T06:39:52", "published_display": "05 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownersh", "url": "https://finviz.com/stock?t=PCVX&ty=ocv&ov=chain_date", "source_name": "Finviz", "published_at": "2026-07-04T19:10:41", "published_display": "04 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Updates VAX A1 Trial, Is It Still A Bargain?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Options", "summary": "The article provides comprehensive financial data and trading information for Vaxcyte Inc (PCVX), including its last close price, market capitalization, earnings per share, sales figures, and various performance metrics. It also details insider and institutional ownership, short ", "url": "https://finviz.com/stock?t=PCVX&ta=1&p=m&ty=oc&b=1&r=y5&ov=list_strike&s=25", "source_name": "Finviz", "published_at": "2026-07-04T06:09:46", "published_display": "04 Jul 2026 06:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte stock stays tied to pipeline progress. Nasdaq listing and SEC filings frame the setup.", "summary": "Vaxcyte's stock performance is primarily driven by its pneumococcal vaccine pipeline, clinical milestones, and company disclosures. The company, a US-listed vaccine developer on Nasdaq, has its investor relations information as the main public reference point. Its market valuatio", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/vaxcyte-stock-stays-tied-to-pipeline-progress-nasdaq-listing-and-sec/69681398", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T15:40:09", "published_display": "03 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNcGpCYmQwT3NhTUdVRnFMd0hKQkNBa3Y2UEVzYWtWRkNyOTYwaWxfbmlHQ1VMaGJnd2xzUWcwNUJCSHM1ZDdjdmczY2I2NVNpWVRRVnB4YWRKWUdkeThCX0FlTGJCajlBeU1KdUtWMzVpbHBiZkFZbWMxQWVGcTh2N1BmRjdrMmh6WjgtR255cjdEZmY0SzFaU0JDSFE?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX - Vaxcyte Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Vaxcyte Inc (PCVX). It details various financial metrics, including market capitalization, income, sales, EPS, P/E ratios, and stock performance, alongside insider and institutional ownership statis", "url": "https://finviz.com/stock?t=PCVX&ta=1&p=d&ty=lf&b=1&r=y1&page=20", "source_name": "Finviz", "published_at": "2026-07-03T05:40:09", "published_display": "03 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Insiders Sold Vaxcyte Shares Recently?", "summary": "A recent insider transaction at Vaxcyte (NASDAQ:PCVX) involved Co-Founder Grant Pickering selling US$1.3m worth of shares at an average price of US$55.22, reducing his holding by 5.4%. This was the largest insider sale in the last year, occurring near the current share price of U", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/have-insiders-sold-vaxcyte-shares-recently", "source_name": "Simply Wall Street", "published_at": "2026-07-02T15:40:45", "published_display": "02 Jul 2026 15:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Vaxcyte For: 1 July By Investing.com", "summary": "The article announces the filing of Form 144 for Vaxcyte on July 1st. It also features current market data for indices, commodities, bonds, and shares, along with trending news and top stock movers, including Vaxcyte's stock performance.", "url": "https://uk.investing.com/news/stock-market-news/form-144-vaxcyte-for-1-july-93CH-4754025", "source_name": "Investing.com UK", "published_at": "2026-07-01T23:56:00", "published_display": "01 Jul 2026 23:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items", "summary": "A recently filed Form 144 from Vaxcyte, Inc. (PCVX) indicates that director James Wassil completed three sales of 2,250 shares each on April 1, May 1, and June 1, 2026, generating gross proceeds of $131,475.60, $127,870.65, and $111,416.62 respectively. The filing also details up", "url": "https://www.stocktitan.net/sec-filings/PCVX/144-vaxcyte-inc-sec-filing-42d34689152f.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:39:59", "published_display": "01 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell Small Cap Comp Growth Benchmark", "summary": "Vaxcyte, Inc. (NasdaqGS: PCVX) has been added to the Russell Small Cap Comp Growth Benchmark. This news follows a series of recent developments for the company, including board changes, insider stock sales, and progress in its vaccine trials for various bacterial diseases. The co", "url": "https://www.marketscreener.com/news/vaxcyte-inc-nasdaqgs-pcvx-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f32d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T20:10:55", "published_display": "29 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Vaxcyte, Inc. \u2013 NASDAQ:PCVX", "summary": "This page from TradingView provides financial information for Vaxcyte, Inc. (NASDAQ: PCVX), specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data and trading platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-PCVX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T18:42:56", "published_display": "29 Jun 2026 18:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10 Health Care Stocks With Whale Alerts In Today\u2019s Session", "summary": "This article highlights unusual options activity, known as \"whale alerts,\" for ten health care stocks. It details bullish, bearish, and neutral sentiment trades on specific call and put contracts for companies like Vaxcyte, SELLAS Life Sciences, Hims & Hers Health, and others. Th", "url": "https://www.benzinga.com/markets/options/26/06/60167720/10-health-care-stocks-whale-alerts-today-s-session", "source_name": "Benzinga", "published_at": "2026-06-29T17:40:55", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2000 Growth Benchmark", "summary": "Vaxcyte, Inc. (NasdaqGS: PCVX), a clinical-stage vaccine company, has been added to the Russell 2000 Growth Benchmark. The company is focused on engineering high-fidelity vaccines to combat bacterial diseases, with a pipeline that includes candidates for pneumonia and Group A Str", "url": "https://www.marketscreener.com/news/vaxcyte-inc-nasdaqgs-pcvx-added-to-russell-2000-growth-benchmark-ce7f5fdede80f027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:28", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing", "summary": "An insider at Vaxcyte, Inc. recently sold shares totaling $1,338,270, as reported in a new SEC filing. This transaction occurred on June 29, 2026, and follows a previous insider share sale on June 22, 2026. Vaxcyte is a clinical-stage vaccine company developing high-fidelity vacc", "url": "https://www.marketscreener.com/news/vaxcyte-insider-sold-shares-worth-1-338-270-according-to-a-recent-sec-filing-ce7f5fdedc8dfe21", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T07:40:55", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vaxcyte\u2019s (PCVX) Russell Index Debut Quietly Reframing Its Long\u2011Term Governance And Growth Story?", "summary": "Vaxcyte (PCVX) was recently added to several Russell growth indices and refreshed its board, with Moncef Slaoui joining as an independent director and Jacks Lee transitioning to a manufacturing consultant role. While these moves are positive for profile and governance, the primar", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/is-vaxcytes-pcvx-russell-index-debut-quietly-reframing-its-l", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:11:00", "published_display": "29 Jun 2026 01:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) CEO and family trusts sell 24,237 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSUd4S2dEVjVGdVBRQUg2M0VseElwbFh0X19ZdkFray1hamxqVUZZalRtQ0RpQkJSMWVJMllGRTduaGlmLXNzR0hUZktfTFNvbk5SSlRLd3Q1V0lXanNHVWswbUx6NW1FcVVtRkYxNmpsTktNWE5qR00zOWVtMmJMMksxNzMzbzg0cFBpeHpXbkxpVXRYT0pWY3dBbmppRnhZZnlVNGNxa0c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moncef Slaoui gets 26,061 Vaxcyte (PCVX) options at $52.11 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPRGpJUGRRSFUxZ2tNTmVqTHJuYmpXU3FiMm9GWDdXSVFyYThSVXZDM1g4aWJfcFpZeFp2RFRscDZEN1c0SHU0UlJwc1ktTGxIMWNnMC16M0RJcUNxYzBoY0ZfMERRRkRYMmxFZS1CQnZvM1hzVXEtR3ljS3BWZ0o0S09DUW12RG0zbVducGxsT0kzcUNiY3pYZUUwWFBWZkFFSDhJNmNNaHM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moncef Slaoui joins Vaxcyte (NASDAQ: PCVX) board as director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQRFN5UTN5QkhSNjlnR3U2N0FUcEFReVhqRzhZN1BSbmtEZ3JQZ2VLQ0tfSko5VlBxRElxSUFtaGF1SXBqYktvWkZDRnp4Y1UyMkdFMzhxT3FjWldSdUNrRmhTVktWRVdZR0xueUJrRW50cTRoTzBHWnQ4UVQwSjZKb0ozRGQxN3V0aEQ1WnVFbmhRNEotRDA4TTE1Q2lBaDdULWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNUGNxWWpxM3dVYmdXVGRpMF8zNnN5THBLdnJHY1VyLTNwSkFxZVFrekNhS2RCd0lLYzhoVUlJbE93NVhKRFhWaGIzVGcwaHpMdHBRTmNfQVhQNXVwbjZIZE1ub3M3bV91QXU3X0gteVp0N2VRUmVzblNnMVJMVjlyQzQ0MjJxRmZCcWJkN2lucE9iNllRNjFHT0FhS3JWOVJ2RWcyV1BfVzFsZW9zd1NkS1pxRHZvRUE5X1lkT2tBSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vaxcyte-pcvx-doses-first-patient-141404145.html", "source_name": "Insider Monkey", "published_at": "2026-06-22T14:14:04+00:00", "published_display": "22 Jun 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vaxcyte-insider-sold-shares-worth-080640766.html", "source_name": "MT Newswires", "published_at": "2026-06-22T08:06:40+00:00", "published_display": "22 Jun 2026 08:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (NASDAQ: PCVX) CEO sells 24,461 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTFB6Nk9tWmVFUl9uMG5zYWJSTExrQ0p0ZWd2dEluRUVVWk80V2pPdUdRVFpTYUNVNkRJVnlfQ3ZjdVd2Ni1ocHZLN2pLbFRMbTVscENkMHhSMzczblZhcjhtalBWZWRuV2VPQzd6bjRsX1FITl9xLV9CY0s3UThiMzVOSVRhZ0VNbWhDT2pHQk1Kb2drT0F1ckJaallza2xoV2ZXYkFVb2Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) CFO sells 10K shares under 10b5-1 plan, holds 166K+", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWWJyT3o1bnhLaDd1NVBFZTVRM3F6YW5oemFsWGNYSU81S3p4S0pSMEVaUkhjQVRNRURFQmJ1VlJtSGdkTk9ubm1jbFZaQUlCV1pjQlV2bjV0QXU2a1haa1lfR2ZxU3RBSUx4dnNvR3hYZUt1My1aeHM1aEhLYXI3TjJKcW5kdzJSai10a0E1SEk1anFWSWdOVU1Rc25ZR3Q1UHhTYl9CRXo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/vaxcyte-pcvx-conducts-initial-dosage-155536532.html", "source_name": "Insider Monkey", "published_at": "2026-06-17T15:55:36+00:00", "published_display": "17 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vaxcyte-doses-first-participant-phase-200500210.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:05:00+00:00", "published_display": "02 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Promising 112% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcGVSVUJod2xKcHZKMGpITUNoVGpXTlVPS3oxdmxlb2lIOTI2STRQdlpiN0xjdDFOV0pYbVN4VlRZcTR4UklDTXY3ZVI0WVRSdlRDTExCaXM2cThJYUZfRVlvOXRQeFVWaFgtV3pTVUVJWUVUVHZoTVpsamZxM1NlOEJmV1NTMmZxVTJwWDgyRFJYem02NTF2LTlGVXV2Rkowajh0cWJoQ1hUc29MV2tCN1YzSENNLWZLN0o5VlV6VDJULXptZTkzXzVEMlVkNnhhQ3JJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/why-vaxcyte-pcvx-8-7-061211721.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T06:12:11+00:00", "published_display": "01 Jun 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOSm13WXoxbHJDVm0wUUJLSHBpZGJWVjJMbVZLMmo0MUtyXy13VUE4M3lfRXBIZzc1dDJKX0ZqU3I4RlVkc3lJYlhpbTYzc1JzVHlwZ2J0VUhnQUZ2aWVvSHhMX3IxNER3elpYT1dVN1BUZndrUTh0LVA5YXBWbzh3X3kyS1lDc1VDQjZIcmFyRzFPVXR2TC1WamExOGx1aHRNajZPSUh6LXVHU0ZIVkctLVBvdE1ZajdicmtweGxNaDdKMVNTMnBCbDZocw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte completes three Phase 3 vaccine enrollments; Q4 data next", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRW9QTXpna0pDUVBaTmdpM2FpUmJvOFF6M203bXBmaXJSS1c5TWxFM2dJYnBrQmdfaTZuU2VGQmFRd05SUXl1aUx5NDN4RjRtZVl0ajBpeUFfaGtVd2tpU21NTmJleXNSMHR0WHhNdERwZFZadXB1Ym9pYzFnTFZyZnlTb1o3VU9nR1lsRmxVS21KUGNRVkE2YlhGVzkyTkNDenducTlSX1VwYzNkN0hQTjdrN3FpM1JCV21iSw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPUE1WaWpJU2xwOGJqZlJOamZxM3hoam0yOEljUkwwUk9pYU93UENKT2NmN1F0Sl9vQ0ktVUZlUG51NEhsVFRicjExVks1SVlMUkpkS2o0V29RTGdpUzdSX3FweG9Cb2NRczh4dVJ5Y1BMM0hVSjF3SzJyeEJYVTFKTmliazJuRTlSQzI5NWlGUlFXMkhpYmtNWlVrbDgxQ1ByR2ExMS1MM3QwU0FxUi1IR0x4X085RUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte fills key adult vaccine trial, sets up 2026 Phase 3 data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQ3J0RE1aM1RzZWRpRXAxTXRuM1hiQW1Mb3NmVmZXQVBnaHBJandxQ0NRczNMODhsd01BamdFclNxTG83MWpPckdwa09ZNGpxTjU2Z1RkNW00ZlVUNXgyYTJOLXFFYVBla3VPMUdVV0RtQkRhazhuZkJENTh1cUtRQjJKUTRFa3FFMDQ2VWF6UWJ3RVpGSm4tc1Q5bnVlX0pGZ3l3c2NZTVdvZVFzS3pmNmlqZGg0WF9rS0tr?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE5oekZPd0huTk9IVzM2Q3hqa0tRMTA1cWRudzBQbFF5TXgyR3J2bTQ3SnFiVEtMSDkwWnNzTWoxTEZ6eGFhVm5rMDB4TzdmME1uVFVYc1pIMFp0d0s3Ym1BQmpnOGxiR2dkQ2dzeHo5T0ZnRmZvVXpCUHc5Q3Fndm8?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Vaxcyte (PCVX) So Attractive", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOaVNCSFdRRm5Ta0M4MEhnREJrYVZGWVpsTVNxQzB5b1pab3JfU256VEQzOFBBVHZqYXZMUTlTbE9Sb3g4MWgtc1o0aU9Wa0lRX045OTdUYW5iemFCcUNkb2JLdmxvMVdIZV83NGgxUDFheVhVbmlKS3cxY3NKQWkxTg?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-07T07:00:00+00:00", "published_display": "07 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte (PCVX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9YT3FId1YyNm01M2psSkJ6eFFiblZMb0R6V2lpY091YUxKZ2x0QjZUekVBdzlHcWN5c3FheWJsWmhWLUZtWVg0dXRLMHN0Y3RpMEpB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T21:41:03+00:00", "published_display": "24 Apr 2025 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNeTRWRlhWcmctdVc1bVBxWUpVZTlOaDZZbERfUVhyYTFMelpxeDlfTjVzYlliWnIyU0FyVXBIaHFaWEFuTW9NVFlyMUxyWVk1dFd6cTQtTWpSR3NmZ3JrLTlqWFFQY29rS1RIODkyaDVDRjhPU3JfV0FNdFJROGwtY2czWjd4cGk5ZDZVTXV6eVhwaVNOSzdwanNtdHNsNWdYNXk3LTJNRVRlM3FKWk1Kd2o3emM?oc=5", "source_name": "BioProcess International", "published_at": "2025-02-27T08:00:00+00:00", "published_display": "27 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 58, "sentiment_summary": {"positive": 14, "negative": 5, "neutral": 39, "score": 54, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 23.45, "count": 42}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 58.21, "latest_week": "2026-07-10", "one_week_move": -0.3, "four_week_move": 22.7, "twelve_week_move": -6.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.159339, "market_dynamics_buy_signal": false, "relative_strength": 5.593165, "fair_value_gap": -4.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.8601, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.3% over one week, +22.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 55, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 8}, {"label": "Simply Wall Street", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "DirectorsTalk Interviews", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 42}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.3% over one week, +22.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Vaxcyte (NASDAQ: PCVX) adds independent director John Markels, sets $430,000 equity grant"}], "updated_at": "2026-07-16T00:49:58.986788+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}